Skip to content

A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy

A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003002
Enrollment
Unknown
Registered
2020-02-13
Start date
2020-02-05
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe novel coronavirus pneumonia (COVID-19)

Interventions

Sponsors

Huangshi Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Hospitalized patients with novel coronavirus pneumonia confirmed by pathogenic detection 2. Meet any one of the criteria for severe type: 1) Respiratory distress: RP >= 30/min; 2) At rest, the oxygen saturation <= 93%; 3) Arterial partial pressure of oxygen (PaO2)/Fraction of inspiration (FiO2)(Oxygenation Index, P/F) <= 300mmHg. 3. Aged 18 to 75 years; 4. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregancy or lactating women; 2. People with allergies or allergies to components of Truncated Torsion formula; 3. Patients with serious basic diseases such as malignant tumor, cirrhosis, chronic renal failure (uremic stage), hematological disease, HIV, etc.; 4. Patients with obstructive pneumonia caused by lung tumor, pulmonary fibrosis, alveolar proteinosis and allergic alveolitis; 5. Patients with long-term use of hormone, immunosuppressant and other drugs; 6. Severe mental illness or inability to cooperate with investigators.

Design outcomes

Primary

MeasureTime frame
14 day outcome of the subjects, including: recovery, improvement, turning critical, death.;lung CT;

Secondary

MeasureTime frame
Routine Blood;APACHE II;oxygenation index;vital signs;major organ function;Coagulation index;inflammatory biomarkers;

Countries

China

Contacts

Public ContactTingrong Huang, Bangjiang Fang, Jun Feng, Jianguo Zuo, Gang Wang

Huangshi Hospital of Traditional Chinese Medicine

fangbji@163.com+86 0714-6224162

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026